Merck MRK recently launched two late-stage clinical studies to evaluate MK-8527, its investigational once-monthly oral pill for HIV pre-exposure prophylaxis (PrEP). The EXPrESSIVE-11 study, which ...

"We're empowering patients and caregivers to take control of their health," said Jay Lenick, Tenovi's Chief Revenue Officer. "With the Tenovi Pillbox, individuals can stay on track with their ...

Recognizing that the gastrointestinal (GI) tract plays host to several different biomarkers that could potentially be useful ...

A new tablet-based drug is showing great promise for both type 2 diabetes and obesity — and unlike existing GLP-1 medications, it doesn’t reduce appetite or cause muscle loss. Early studies suggest ...